Two Draft Guidances Address Trial-Related Adverse Events
Executive Summary
Clinical trial investigators, not sponsors, should ensure medical care for trial subjects who experience research-related adverse events, a recently issued FDA draft guidance says
You may also be interested in...
IRB Handovers Harmonized In Eight-Fold Path Outlined By FDA, OHRP
Joint draft guidance on institutional review board switching for industry- and federal government-sponsored clinical trials advances the agencies’ goal creating umbrella coverage in human subject protection.
Adverse Event Reporting In Clinical Trials Can Flow Through Sponsors – FDA
Drug trial sponsors can supervise reports of "unanticipated problems" to Institutional Review Boards under an FDA 1draft guidance on adverse event reporting
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.